SCNX Latest Press Releases

-- October 13, 2026 --

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth Globe Newswire 8:05 AM

-- October 2, 2026 --

SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals Globe Newswire 8:05 AM

-- September 30, 2026 --

Scienture Holdings, Inc. Announces Reverse Stock Split Globe Newswire 4:05 PM

-- September 22, 2026 --

SCIENTURE Expands Commercial Reach of REZENOPY to Addiction Treatment Centers through an Agreement with a Distribution Partner Globe Newswire 8:15 AM

-- September 9, 2026 --

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 Globe Newswire 8:55 AM

-- August 14, 2026 --

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Globe Newswire 8:08 AM

-- August 12, 2026 --

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY , the Highest Dose FDA-Approved Naloxone Nasal Spray Globe Newswire 8:05 AM

-- July 9, 2026 --

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (naloxone hydrochloride) to Wholesalers Globe Newswire 8:05 AM

-- June 18, 2026 --

SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide Globe Newswire 8:05 AM

-- June 9, 2026 --

SCIENTURE Secures Formulary Coverage for REZENOPY with a Large National Health Plan and Expands Commercial Team Globe Newswire 8:05 AM

-- June 4, 2026 --

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC ACCESS Newswire 8:00 AM

-- June 2, 2026 --

SCIENTURE Receives U.S. Patent Covering REZENOPY (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 Globe Newswire 8:05 AM

Market Data Delayed 15 Minutes